Watertown, Mass. — Enanta Pharmaceuticals reported a wider fiscal third-quarter loss as the biotechnology company continued to advance its respiratory syncytial virus and immunology drug programs.
For the three months ended June 30, 2026, Enanta reported revenue of $14.4 million, down from $18.3 million a year earlier. Revenue consisted of royalties from worldwide sales of AbbVie’s hepatitis C treatment MAVYRET/MAVIRET.
The company posted a net loss of $19.5 million, or 67 cents per diluted share, compared with a loss of $18.3 million, or 85 cents per share, in the same period last year.
Research and development expenses declined to $22.1 million from $27.2 million, reflecting lower clinical trial expenses for Enanta’s RSV programs, partially offset by higher spending on its immunology programs.
General and administrative expenses fell to $9.5 million from $10 million, primarily due to lower stock-based compensation expenses.
Enanta ended the quarter with $211.5 million in cash, cash equivalents and short- and long-term marketable securities. The company said its existing resources, together with retained future royalty revenue, are expected to fund operations into fiscal 2029.
“During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and CEO of Enanta.
Enanta has begun dosing patients in LOTUS, a Phase 2b trial evaluating its investigational RSV treatment zelicapavir in children. The study is expected to enroll about 150 hospitalized and non-hospitalized children between 28 days and 36 months old who test positive for RSV.
Topline results from LOTUS are expected in 2027.
The company also plans to begin RESOLVE, a registrational Phase 2b/3 study of zelicapavir in high-risk adults with RSV, in the fourth quarter of 2026. The trial will include patients at greater risk of severe disease, including adults age 75 and older and those with chronic obstructive pulmonary disease or congestive heart failure.
Topline results from the Phase 2b portion of RESOLVE are expected in 2027.
“With no approved antiviral therapies currently available for RSV, we believe zelicapavir is uniquely positioned to address a substantial unmet need across both high-risk adult and pediatric populations,” Luly said.
Enanta is also developing EDP-323, another once-daily RSV antiviral candidate that could be used alone or in combination with zelicapavir.
In immunology, the company expects to report topline data in the fourth quarter of 2026 from a Phase 1 trial of EDP-978, an oral, once-daily KIT inhibitor being developed for chronic urticaria and other mast cell-mediated diseases.
Enanta is also advancing EPS-3903, an oral STAT6 inhibitor being developed for atopic dermatitis and other inflammatory diseases. The company plans to file an Investigational New Drug application for the candidate in the second half of 2026.
A third immunology program targeting MRGPRX2 remains in preclinical development, with Enanta expecting to select a development candidate during the second half of the year.
Separately, Enanta said partner AbbVie received European Commission approval in June for MAVIRET to treat acute hepatitis C infection in adults and children age 3 and older. Glecaprevir, one of the two antivirals in MAVIRET, was discovered by Enanta and continues to generate royalty revenue for the company.
